Eltrombopag is named as a drug or biological intervention in 4 clinical trials in our China, UK, USA and India trial registers, 1 of which is recruiting. Lead sponsors include Institute of Hematology & Blood Diseases Hospital, China (2), Novartis Pharmaceuticals (1) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). Registered phases: Phase 2, Phase 3 and Phase 4. Conditions studied include Primary Immune Thrombocytopenia; Primary Immune Thrombocytopenia (ITP); Chemotherapy-induced Thrombocytopenia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04600960 | Eltrombopag for Chemotherapy-induced Thrombocytopenia (ClinicalTrials.gov ↗) Chemotherapy-induced Thrombocytopenia, Eltrombopag |
Phase 2 | Recruiting |
| NCT07189910 | Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP (ClinicalTrials.gov ↗) Primary Immune Thrombocytopenia (ITP) |
Phase 4 | Not yet open |
| NCT07687134 | Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP (ClinicalTrials.gov ↗) Immune Thrombocytopenia |
Phase 2 | Not yet open |
| NCT05653219 | A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (ClinicalTrials.gov ↗) Primary Immune Thrombocytopenia |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Primary Immune Thrombocytopenia | 1 |
| Primary Immune Thrombocytopenia (ITP) | 1 |
| Chemotherapy-induced Thrombocytopenia | 1 |
| Eltrombopag | 1 |
| Immune Thrombocytopenia | 1 |
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Novartis Pharmaceuticals | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Register | Eltrombopag trials |
|---|---|
| Clinical trials in China | 4 |
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Eltrombopag works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Eltrombopag (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.